FriesJ.F., HunderG.G., BlochD.A.The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum1990; 33: 1135–6.
2.
JennettJ.C., CalkR.J., AndrassyK.Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum1994; 37: 187–92.
3.
ScottD.G.I., WattsR.A.Classification and epidemiology of systemic vasculitis. Br J Rheumatol1994; 33: 897–9.
4.
WattsR.A., CarruthersD., SymmonsD.P., ScottD.G.I.The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol1994; 33: 832–3.
5.
WattsR.A., CarruthersD.M., ScottD.G.I.Epidemiology of systemic vasculitis: changing incidence or definition?Semin Arthritis Rheum1995; 25: 28–34.
MathiesonP.W., LockwoodC.M., OliveiraD.B.G.T and B cells responses to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Immunol Immunopathol1992; 63: 135–41
13.
LockwoodC.M.Specificity and pathogenicity of antineutrophil cytoplasm antibodies. Exp Nephrol1993; 1: 13–18.
14.
ZhaoM.H., JonesS.J., LockwoodC.M.Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Expl Immunol1995; 99: 49–56.
15.
LaiK.N., LeungJ.C.K., RifkinI., LockwoodC.M.Effect of antineutrophil cytoplasm antibodies on the intracellular calcium concentration of human neutrophils. Lab Invest1994; 70: 152–62.
16.
KeoganM.T., RifkinI., RondaN., LockwoodC.M., BrownD.L.Anti-neutrophil cytoplasm antibodies (ANCA) increase neutrophil adhesion to cultured human endothelium. Adv Expl Med Biol1993; 336: 115–19.
17.
MathiesonP.W., CobboldS.P., HaleG.Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med1990; 323: 250–4.
18.
LockwoodC.M., ThiruS., IsaacsJ.D., HaleG., WaldmannH.Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet1993; 341: 1620–2.